The raised revenue guidance midpoint and expanded operating margins signal accelerating operational leverage. The $1.0B buyback adds a capital return catalyst. Monitor the G7 15 Day international rollout and Stelo adoption for sustained growth trajectory.
Price Chart
Executive Summary
Dexcom reported Q3 2026 revenue of $1.344B (up 11% YoY), above the $1.33B consensus, and non-GAAP EPS of $0.73, above the $0.67 consensus. The company raised its full-year revenue guidance midpoint to $5.20-$5.25B and announced a $1.0B share repurchase authorization.
Key Financial Metrics
Key Facts
- Q3 2026 revenue of $1.344B, up 11% YoY, above $1.33B consensus
- Non-GAAP diluted EPS of $0.73, above $0.67 consensus
- GAAP diluted EPS of $0.72 vs $0.70 in Q3 2025
- GAAP operating income of $327.2M, or 24.3% of revenue, up 420 bps YoY
- Non-GAAP operating income of $339.5M, or 25.3% of revenue, up 270 bps YoY
- U.S. revenue grew 14% YoY; international revenue grew 5% YoY
- Raised FY 2026 revenue guidance to $5.20-$5.25B (12-13% growth)
- Raised FY 2026 Non-GAAP Operating Margin guidance to ~24%
- Raised FY 2026 Adjusted EBITDA Margin guidance to ~32%
- Announced $1.0B share repurchase authorization through Dec 31, 2027
- Cash and marketable securities of $1.82B as of Sep 30, 2026
Financial Impact
Revenue beat consensus by ~$14M; EPS beat by $0.06; guidance raised; $1.0B buyback authorized (~3.4% of market cap)
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| United States | $969.8M | +13.8% |
| International | $374.7M | +4.8% |
Risk Factors
- International revenue growth slowed to 5% YoY vs 26% in Q1 2026
- GAAP net income declined to $275.1M from $283.8M in Q3 2025 due to lower other income
- Share repurchase authorization does not obligate execution and may be suspended
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001093557-26-000193 |
| Document: dxcm-20261029.htm | 0001093557-26-000193 |
| Document: 0001093557-26-000193-index-headers.html | 0001093557-26-000193 |
| Document: 0001093557-26-000193-index.html | 0001093557-26-000193 |
| Document: 0001093557-26-000193.txt | 0001093557-26-000193 |
| 8-K Data (Synthetic) | 0001093557-26-000193 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 29, 2026 3d ago | 8-K | $80.24 | awaiting T+20 | awaiting T+20 | $82.29 (+2.55%) |
Oct 27, 2026 5d ago | 144 | $78.62 | awaiting T+20 | awaiting T+20 | $82.29 (+4.67%) |
Sep 16, 2026 6w ago | Insider Cluster | $87.93 $87.71 | ▲ +0.25% | ▲ +1.46% | $82.29 (+6.41%) |
Sep 14, 2026 6w ago | 8-K | $86.45 $85.06 | ▼ −1.61% | ▼ −4.33% | $82.29 (−4.81%) |
Aug 28, 2026 9w ago | Insider Cluster | $91.06 $86.64 | ▼ −4.85% | ▼ −4.67% | $82.29 (−9.63%) |
Aug 24, 2026 9w ago | Insider Cluster | $89.16 $87.73 | ▼ −1.60% | ▼ −1.85% | $82.29 (−7.71%) |
Aug 17, 2026 10w ago | Insider Cluster | $89.60 $87.34 | ▼ −2.52% | ▼ −0.78% | $82.29 (−8.16%) |
Jul 21, 2026 14w ago | Insider Cluster | $71.43 $89.78 | ▲ +25.69% | ▲ +22.80% | $82.29 (+15.20%) |
Jun 17, 2026 19w ago | Insider Cluster | $72.47 $77.98 | ▲ +7.60% | ▲ +7.07% | $82.29 (+13.55%) |
May 26, 2026 22w ago | Insider Cluster | $70.17 $69.75 | ▼ −0.60% | ▲ +1.69% | $82.29 (+17.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers